Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued at up to $600 million in upfront cash and milestone payments, the acquisition is the largest in Merz's history.
"This acquisition represents an important strategic milestone for Merz," said Philip Burchard, CEO of Merz Pharma Group, which has affiliates in 18 countries around the world. "We have a vision to be the most innovative company in aesthetics, and expanding into the rapidly growing field of energy devices will position us for long-term success in this area. The addition of Ulthera's energy device technology complements and expands our global presence in the aesthetics space."
Founded in 2004, Ulthera is a leader in non-surgical lifting and tightening treatments. Using therapeutic ultrasound technology, the UltheraŽ System is the first and only ultrasound platform device to receive FDA clearance for lifting skin on the eyebrow, the neck and under the chin. Ulthera expects sales of more than $100 million in 2014.
"The aesthetic lift indication differentiates Ulthera from every other energy device available in the market today," said Bill Humphries, President and CEO of Merz North America, Inc. "It is truly innovative technology, and we expect to leverage our in-house clinical expertise to develop further aesthetic and medical applications and bring them to the international marketplace."
Merz and Ulthera have a shared mission: to bring innovations to market that meet the needs of physicians and improve the well-being of patients. This shared long-term vision provides a solid foundation for the combined company. "Joining with a like-minded, growing global healthcare company is a major milestone in the life of our company," said Ulthera CEO Matt Likens. "Through our collaboration with Merz, we hope to introduce the UltheraŽ System to new customers and markets around the world."
"Building on this important new partnership, Merz will continue to seek innovative M%7EA and licensing opportunities on a global scale," said Hans-JÖrg Bergler, Head of Corporate Development for Merz Pharma Group.
The transaction has been approved by the boards of both companies and is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the third quarter of 2014.